samedan logo

 
 
spacer
home > pmps > winter 2021 > overcoming the challenge of accurate supplier labelling
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Overcoming the Challenge of Accurate Supplier Labelling

Mergers and acquisitions are all too common for pharmaceutical manufacturers. While the combination of two companies has its benefits, it doesnít come without growing pains and challenges. Take, for example, labelling. A merger can result in decentralised labelling processes with inherited home-grown systems and a new array of third-party suppliers, contract manufacturers, re-packagers, and re-labellers. It can also lead to expansion into new geographic markets; each with their own country-specific labelling requirements.

As growing pharma manufacturers work to address these challenges, the importance of label accuracy canít be understated.

A decentralised approach to labelling makes achieving label accuracy and consistency a complex task that can be a major threat to profitability, drag down efficiency, reduce agility, and impact speed-to-market.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.


spacer
Ken Moir, Vice President at NiceLabel, has over 25 years of experience as an international technology sales and marketing leader, and was a partner in two high-tech start-ups, as well as a member of the management team at Zebra Technologies. He has extensive international technology sales and marketing experience, specifically in the fields of product, channel, vertical, and alliance sales and marketing. Ken is an automatic identification and data capture (AIDC) industry veteran with diverse market and technology knowledge, including barcode, radio frequency identification (RFID), mobility, SAP, and label management solutions.
spacer
Ken Moir
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

EUROPEAN CHMP ADOPTS POSITIVE OPINION FOR KITEíS KTE-X19 FOR THE TREATMENT OF RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA

-- If Approved, KTE-X19 will be an Important New Advance for this Disease with a Poor Prognosis -- -- Kite would Become the First Company with Multiple Approved CAR T Therapies in Europe --
More info >>

White Papers

What is process characterization?

EXPUTEC

Process characterization is an essential step in the commercialization of a new (biological) drug. For drug product commercialization, manufacturers must validate the drugís manufacturing process. This ensures that the manufacturing process delivers consistently a quality product and that the patient is not at risk.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement